Workshop 3 Topic: Bio-isosteres and derivatives 1. Carefully examine the below drug, and suggest two bio-isosteric modifications for the heterocyclic ring in furosemide without changing activity. 00 0 H₂N S O b OH a ZI N N C H N CI Furosemide Ring name Ring Physicochemical properties P NI ZI N e Suitability as bio-isosteres

Workshop 3 Topic: Bio-isosteres and derivatives 1. Carefully examine the below drug, and suggest two bio-isosteric modifications for the heterocyclic ring in furosemide without changing activity. 00 0 H₂N S O b OH a ZI N N C H N CI Furosemide Ring name Ring Physicochemical properties P NI ZI N e Suitability as bio-isosteres

Organic Chemistry

9th Edition

ISBN:9781305080485

Author:John E. McMurry

Publisher:John E. McMurry

Chapter22: Carbonyl Alpha-substitution Reactions

Section22.SE: Something Extra

Problem 63AP: As far back as the 16th century, South American Incas chewed the leaves of the coca bush,...

See similar textbooks

Similar questions

question 17
question 16
Predict the products, if any, of the following reactions. 20-35 (a) ascorbic ac (1) LiAlH4 -COOH (2) H3O+ (b) (1) NaCN CH₂Br (2) H3O+, heat (c) (1) SOCl2 (d) KMnO4, H₂O oct-4-yne (warm, concd.) (2) AlCl3 COOH (e) CH₂OH Na2Cr2O7, H2SO4 (f) Ph (1) BH3.THF CH3CH2-CH-COOH (2) H₁₂O+
CHEM-240-x1-x2- X 09 KEY Stereoche X *Organic Chemist x functional groups X 08 KEY Constitutic X *Molecular Model X b Draw the lowest Course: NEUR-35 X A https://moodle.viterbo.edu/pluginfile.php/1286283/mod_resource/content/0/Molecular%20Models%20Lab%20assignment%202.. Not syncing A) Read aloud 7 Draw E Highlight O Erase 3 of 4 5. Draw (15,3R)-1-bromo-3-methylcyclohexane in its lowest energy conformation. 6. а. Draw the following molecule as a flat ring skeletal structure with correct stereochemistry. H b. Is the chair in 6a. in its lowest energy conformation? Provide your rationale. 11:31 AM O Type here to search 9. 10/5/2020 +
Propose a structural formula for compound A, C5H13N, given its IR and calculated 1H-NMR spectra.
Provide a structure for the given compound. molecular mass 101; -1. IR: 3397, 3200, 1655, 1622 cm¯¹; 13C NMR: 8 27.5, 838.0 (weak), 8 180.5 (weak). Draw the compound. Select / ||1||| Draw C H N Templates O More
Unknown B: Soluble in water Bubbles upon contact with 5% NaHCO3 and forms a homogenous solutionWhat functional group is most likely present in the sample?
Suggest mechanisms for the following:
5. (Chapter 15 - Q41b) Propose a structure for the compound that fits the following description. C30H14 7.0 8, (4H, broad singlet) 2.85 (1H, septet J = 8 Hz) 1.20 5 (6H, doublet J=8 Hz) 2.28 6 (3H, singlet) IR: 825 cm 1 5(a) Degree of the unsaturation of this compound is= 5(b) Two peaks at 2.85 o and 1.20 õ indicate that the compound has. group = 4(c) A peak at 2.28 õ indicates that the compound has. group= 4(d) IR absorption indicates the compound is .-disubstituted = 4(e) The name of the compound is =
kindly sopve step by step
( do 14 a )
[Answer All Parts] [50 Marks] Part (a) The following compound 1 shows anticancer activity through Tankyrase inhibition. Further work led to the development of a 1-D QSAR equation for structure 2 shown below. Question 2 (i) (ii) (iii) OH qa R MeO 1 F 2 Logl/C=0.398 +1.089 +4.541 OH OH Propose a workplan that can be used to identify the pharmacophore for 1 and explain what relevant information will be obtained from each product of your synthetic transformations (detailed synthetic methods are not required). [20 marks] Predict the biological activity for 2 where R = OMe, Br, and NO₂. [10 marks] Structure 3 was identified as the new lead from 3-D QSAR studies. Unfortunately, compound 3 suffered from poor water solubility. Propose a prodrug for 3 that will have enhanced water solubility, include a synthesis for your proposed prodrug and explain how the lead will be released in vivo. [20 marks]